To ask the Secretary of State for Health and Social Care, what progress he has made on the acquisition of Orkambi for the NHS.
27 November 2018
The National Institute for Health and Care Excellence (NICE) and NHS England are in dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding.